Solly Chedid, MD, Describes the Landscape of Upcoming MDS Agents
By Solly Chedid, MD, Andrew Moreno - Last Updated: July 25, 2024Solly Chedid, MD, a hematologist and medical oncologist at Singing River Health System in Gulfport, Mississippi, gave Heme Today an update on upcoming agents for treatment of myelodysplastic syndromes (MDS).
Advertisement
Regarding frontline MDS care, Dr. Chedid quickly overviewed the multifaceted superiority luspatercept demonstrated over epoetin alfa in the COMMANDS trial. He also described how specific agents in second-line care show promising transfusion independence results, though with potential for myelosuppression.
Advertisement
Related Posts
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
Overall survival, nonrelapse mortality, and relapse rates were also assessed in the phase 2 trial which had these results.
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Juan Jose Rodriguez-Sevilla, MD, PhD, summarizes current clinical knowledge about inflammation within MDS pathobiology.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.